Navigation Links
Delpor Awarded $340K NIH Grant for 3-month Long Acting Risperidone Product in order to Improve Medication Adherence in Schizophrenia and Bipolar Disorder


Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced the awarding of a $340K grant from the National Institute of Mental Health for the further advancement of the company’s 3-month risperidone product (DLP-114). The product is based on Delpor’s Prozor technology and is expected to deliver therapeutic levels of risperidone for a period of at least 3 months in order to improve medication adherence.

"We are honored to receive this grant award and extremely grateful to the National Institute of Mental Health for believing in our vision." said Tassos Nicolaou, President and CEO of Delpor. "We look forward to employing these new funds to further develop our risperidone program which is expected to offer tremendous treatment benefits to patients suffering from schizophrenia or bipolar disorder.”

Lack of medication adherence is one of the most frequently cited unmet needs in the treatment of schizophrenia and bipolar disorder and it is a major reason that neuroleptic drugs are not more effective in keeping people with schizophrenia out of the hospital. It is estimated that lack of medication adherence accounts for approximately 40% of all relapse. With each successive relapse, the patient’s long-term prognosis deteriorates and previous level of functioning is rarely achieved. Current long acting systems have shown some improvement, but also have certain limitations.

Tassos Nicolaou continued: “DLP-114 is expected to overcome several limitations of the current depot injections. More specifically, the system is expected to further improve medication adherence by extending the release from a couple of weeks to several months, offer full reversibility in case the patient has a treatment related adverse event, and reduce side effects by providing a consistent and superior pharmacokinetic profile.” Mr. Nicolaou concluded by saying: “This is not just about improving medication adherence. It is about addressing an important unmet medical need and improving clinical outcomes for patients suffering from a chronic and disabling brain disorder.”

About Delpor, Inc.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic and without the need for any surgical sutures. Delpor’s device can deliver small & large molecules within a predefined therapeutic window over several months while maintaining zero-order release pharmacokinetics. Delpor is focusing on the delivery of antipsychotics (in order to improve medication adherence, tolerance, and safety) as well as biologics in order to improve patient safety and convenience. The company’s lead products include 3-month formulations of Risperidone, Paliperidone, and Interferon-alpha. Additional information about the company can be found at

About DLP-114
Delpor’s DLP-114 is a small titanium reservoir designed for subcutaneous implantation and loaded with a proprietary formulation of risperidone. The product is designed to provide a constant therapeutic dose of risperidone each day for a total period of 3-6 months. Additional features include reversibility, immediate onset of action, and no accumulation.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Delpor, Inc.
Tassos Nicolaou, President and CEO
Phone: 415-480-6873
Fax:     415-480-6871

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Produce Safety Researchers Awarded by ABC Research Laboratories
2. Cohera Medical Awarded Platform Patent on its Biodegradable Adhesive Technology
3. CELEXION Awarded Patent on Biosynthesis of Renewable Chemicals
4. Chemring Detection Systems Awarded $9M for Biological Detection Systems
5. Leading German Researcher Awarded Elseviers 2011 Tetrahedron Prize
6. Chemring Detection Systems Awarded $500k for Strategic Research and Development
7. Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year
8. Sloan Research Fellowships Awarded to 126 Young Scholars
9. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
10. Chinese Scientists Zhen-Yi Wang and Zhu Chen Awarded 7th Annual Szent-Gyorgyi Prize for Progress in Cancer Research
11. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
Post Your Comments:
Related Image:
Delpor Awarded $340K NIH Grant for 3-month Long Acting Risperidone Product in order to Improve Medication Adherence in Schizophrenia and Bipolar Disorder
(Date:10/12/2015)... Rochelle, Virginia (PRWEB) , ... October 12, 2015 ... ... LLC announced today that Dr. Srini Srinivasan, has joined the firm as a ... expertise and professional stature enable them to bring extraordinary value to the company's ...
(Date:10/10/2015)... -- Le 8 octobre, l,honorable Doris O. Matsui ... Congrès sa déclaration de soutien à la troisième ... plasma (IPAW), qui se tiendra du 11 au ... Protein Therapeutics Association (PPTA) et ses sociétés ... Sensibiliser l,opinion publique mondiale autour du don de ...
(Date:10/9/2015)... Pa. and ROCKVILLE, Md. ... Inc. ("ITI"), a privately-held biotechnology company developing next ... announced that it has entered into an exclusive ... LAMP-vax products for the treatment or prevention of ... execution of the agreement, Immunomic Therapeutics will receive ...
(Date:10/9/2015)... San Francisco, CA (PRWEB) , ... October 09, 2015 , ... ... with a study that aims to better understand the relationship between weight management and ... more frequently and more accurately from participants using an iPhone app. , The uBiome ...
Breaking Biology Technology:
(Date:10/1/2015)...  Biometrics includes diverse set of technologies used ... as fingerprints, eye retinas, facial patterns, voice patterns, ... has been constantly increasing in India ... addition to the most prominent popular method of ... of biometric authentication are rapidly gaining traction in ...
(Date:9/29/2015)... , Sept. 29, 2015 ... employee productivity while also saving energy , Minimized ... as Low Power Active Mode and embedded Fujitsu PalmSecure ... Fujitsu today shows that good things ... and refreshed models to its enterprise desktop and mobile ...
(Date:9/28/2015)... , September 28, 2015 ... expected to reach USD 12.03 billion by 2020, growing ... Technological advancements such as Backside Illumination (BSI) technique to ... over the forecast period.      (Logo: ... of the chip to reduce loss and, thus, reduce ...
Breaking Biology News(10 mins):